TY - JOUR. T1 - Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. AU - Stadler, Walter M.. AU - Figlin, Robert A.. AU - McDermott, David F.. AU - Dutcher, Janice P.. AU - Knox, Jennifer J.. AU - Miller, Wilson H.. AU - Hainsworth, John D.. AU - Henderson, Charles A.. AU - George, Jeffrey R.. AU - Hajdenberg, Julio. AU - Kindwall-Keller, Tamila L.. AU - Ernstoff, Marc S.. AU - Drabkin, Harry A.. AU - Curti, Brendan D.. AU - Chu, Luis. AU - Ryan, Christopher W.. AU - Hotte, Sebastien J.. AU - Xia, Chenghua. AU - Cupit, Lisa. AU - Bukowski, Ronald M.. PY - 2010/3/1. Y1 - 2010/3/1. N2 - BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. METHODS: In this nonrandomized, open-label expanded access program, 2504 patients from the United States and Canada were treated with oral sorafenib 400 mg twice daily. Safety ...
Compassionate use is a treatment option that allows the use of an unauthorised medicine. Compassionate use programmes are for patients who have a disease with no satisfactory authorised therapies or cannot enter a clinical trial. They are intended to facilitate the availability to patients of new treatment options under development"- EMA site. "Global access programmes, known by various names including compassionate use, named patient, expanded access and early access, provide a mechanism by which patients with rare diseases are able to access medicines that would otherwise be unavailable.. For rare and orphan diseases, these programmes can facilitate access to:. -medicines that are in clinical development,. -drugs unlicensed in a specific market but licensed elsewhere,. -drugs under assessment in the marketing authorisation application (MAA) process.. Importantly, through a global access programme, patients can access an orphan drug that may never be commercially available in their home country ...
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushings syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia ...
PARIS, July 11, 2016-- AB Science SA, a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors, announces that the FDA granted a Single Patient IND for Compassionate Use of masitinib for patient with amyotrophic lateral sclerosis. FDA received the first request for single compassionate use of masitinib in...
104317: The market authorisation application for mepolizumab for the indication of hypereosinophilic syndrome (HES) was filed in 2008, but later the file was withdrawn due to outstanding questions from regulators raised from the application. On the basis of sponsors evaluation, participants with life-threatening HES who have documented failure (lack of efficacy or a contra-indication) to at least 3 standard HES therapies (compassionate use) and participants who have participated in a previous GSK sponsored study in HES (long-term access) can be consider for mepolizumab treatment where the country regulation permits. In this study, participants will receive mepolizumab in an open-labelled manner, and limited data will be collected to evaluate the long-term safety and efficacy of mepolizumab.. 201956: This is a Long-term Access Programme (LAP) which aims to support provision of mepolizumab, until it is commercially available, to eligible subjects with severe asthma who participated in a ...
Bexsero (Novartis, New York, New York), the only vaccine in production that protects against MenB, was approved for use in Europe and Australia in January 2013 (1). Its distribution in response to an outbreak marks the first time the "compassionate use" or "expanded access" mechanism for drug approval (2, 3) has been granted to distribute a nontherapeutic biological drug to a group of healthy persons. This unprecedented evolution of events at Princeton has resulted in a flurry of media coverage falling into 3 main categories: support for a cooperative response between public health institutions and the university, concern that students are being used as "guinea pigs" for an untested product, and questions of fairness when many other groups are at risk for disease from MenB ...
Hey all, This is my first time posting so if I am doing something wrong or posting in the wrong place please let me know. I have been following the work of Dr. Wise Young since I got hurt about 3 years ago. I was initially diagnosed as C4-C5 Asia C. I am able to ambulate with a regular walker for very short distances and can do about 30 minutes on a treadmill at a snails pace :) My question is, if and when the trial gets approval for compassionate use, will it be open to incomplete
In addition to being an example of unsubstantiated hype about regenerative medicine, the controversy around the Italy‐based Stamina Foundations unproven stem cell therapy represents another chapter in a continuing debate about how to balance patients requests for early access to experimental medicines with requirements for demonstrating safety and effectiveness. Compassionate use of the Stamina therapy arguably should not have been permitted under Italys laws, but public pressure was intense and judges ultimately granted access. One lesson from these events is that expert regulatory agencies may be the institutions most competent to make compassionate use decisions and that policies should include more specific criteria for authorizing compassionate use. But even where regulatory agencies make decisions based on clear rules, difficult questions will arise. ...
This webinar will cover access to innovative new therapies through expanded access programs with guest speakers Jennifer Miller, PhD, Assistant Professor at Yale University School of Medicine and Alison Bateman-House, PhD, MPH, Assistant Professor at NYU School of Medicine. The webinar will look in detail at the process involved in obtaining an investigational therapy before it gains final FDA approval. Open to anyone looking to learn more about expanded access programs. Register here: http://bit.ly/2I8UvK8
SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- Aethlon Medical Announces Initiation of Compassionate-Use Program to Treat Hepatitis C Virus (HCV).
... Glaxo Wellcome announced today (9/21) that the amprenavir expanded access program is starting for both adults and children (,4 yrs). You or your doctor can call-. 1-800-248-9757 immediately to receive information about enrollment. You or your doctor can call to give the company your doctors name and address. On Sept 28 they will send out expanded access program binders explaining the program. As soon as a person is enrolled in the program drug will be sent out. The company is submitting their NDA to the FDA for accelerated approval in October. Review and approval can take usually from 3-6 months, meaning approval will not come sooner than January 1999.. The program is uniquely offering 3 options for accessing amprenair-. 1. Individuals experiencing adverse side effects from their current PI regimen such as lipodystrophy or elevated lipids but are not failing their current PI regimen can enroll in this option. The purpose is to try and collect ...
Compassionate use is a treatment option that allows the use of an unauthorised medicine. Compassionate use programmes are for patients who have a disease with no satisfactory authorised therapies or cannot enter a clinical trial. They are intended to facilitate … Continue reading →. ...
Therapies that address the underlying cause of PAH are urgently needed. The U.S. Food and Drug Administration (FDA) approved tacrolimus in 1994 for use in lowering the risk of organ rejection in patients undergoing kidney transplant, and it is currently indicated for use in additional organ transplant settings and to treat atopic dermatitis.. Researchers completed a randomized, double-blind Phase 2a clinical trial with 23 class 1 and 2 PAH patients titrated to target blood levels. All target blood levels were well tolerated with no drug related serious adverse events, nephrotoxicity or incident diabetes.. In addition, tacrolimus was provided for compassionate use in three class 3 or 4 PAH patients. The compassionate use demonstrated dramatically reduced rates of hospitalizations and functional class improvements were observed.. We are currently focused on a proprietary formulation of tacrolimus for clinical development program and for commercial use. We are on track to file an Investigational ...
March 13, 2014 - 3:16 pm , By Jennifer Boggs , No comments yet Before its unfortunate drop in quality in its last few seasons, the medical drama House was one of my favorite shows, with its title character, a cranky, possibly drug-addicted doctor solving diagnostic riddles and saving lives with Sherlockian brilliance, and quite often breaking every rule in the book to do it. One episode in particular had House facing off with billionaire investor Vogel, who had thwarted his attempt to enroll a very sick patient in a clinical trial without mentioning to the trial investigator that she wouldnt fit the criteria, namely having just undergone a C-section. They have an impassioned exchange: Dr.: House: Hey! Youre killing her! Vogler: Really? See, I thought you were the one trying to ram her into a drug trial five minutes after surgery. Dr. House: She knew the risks! She was fully informed! Vogler: Yeah, well the guy running the study sure wasnt. Dr. House: Not his life, not his call! Vogler: His ...
The purposes of this study are to make Omegaven® available to cancer patients with liver disease and to determine if Omegaven® can improve or prevent
Usana melatonin side effects is prozac better than zoloft for ocd cefuroxime e coli is effexor xr hard on your liver, Voltaren schmerzgel anwendung pcp price folic acid xtra tab prazosin gits tablets, Buying alprazolam can i buy levoxyl in canada alprazolam ou lysanxia zoloft autism ocd, Penicillin v dosage for adults soma vidalama diclofenac rapid orifarm malegra sildenafil kaufen, Levitra uvp what is oxycodone prescribed for valacyclovir hcl 1 dosage for cold sores xanax per l aereo
We are devoted to providing patients with the highest quality of organically grown medical marijuana. 1-800 medical marijuana treats each and every patient with the courtesy, respect and understanding they so richly deserve.
DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
Expanded access, sometimes called compassionate use, is the use of an investigational medical product outside of a clinical trial (i.e., one that has not yet been approved). At Novelion Therapeutics, and our subsidiary Aegerion Pharmaceuticals, we are committed to increasing awareness of and knowledge about our expanded access programs and the procedures for obtaining access to human investigational drugs. A Message from John Orloff, M.D.
Approval for the lixelle® ß2-microglobulin apheresis column (also called the beta2-microglobulin apheresis column or ß2m). This device is indicated for the treatment of patients with clinically diagnosed dialysis-related amyloidosis (dra ...
London, United Kingdom, Friday 11 April 2014: New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).[1]. As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians discretion for up to 48 weeks. Among patients whose clinical outcomes have been reported, 62% achieved SVR12. Additionally, 62% of patients had improvements in clinical conditions associated with hepatic decompensation (e.g., ascites and encephalopathy) and/or improvement in liver function tests. SOF+RBV±PEG was well-tolerated and led to high rates of virologic suppression.. EASLs European Policy Councillor Professor Patrizia Burra of the Multivisceral Transplant Unit, Padova ...
The treatment currently involves a relatively large number of capsules, so dogs that are difficult to orally medicate wouldnt be great candidates," said Dr Frimberger. "But we are working on reformulating the drug to make it better tasting and easier to administer to dogs before the full trials commence next year.". The MPL program involves two consultations/treatments at the Animal Referral Hospital (ARH) in Homebush, NSW. Owners would have to transport their dogs to and from Homebush for the two treatments. PharmAust will cover all compassionate use program costs, including travel expenses to and from the ARH, as well as costs for the initial conventional chemotherapy treatment upon program completion.. For more information or to enrol, please contact Dr Angela Frimberger on [email protected] What is canine lymphoma? Cancer is the number one cause of death in dogs over the age of 2, with 25 per cent of deaths attributed to cancer¹. "Approximately one in four dogs and one in ...
If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies More than 100 patients are currently treated with metreleptin via a compassionate use program in Europe
Haas J, Linker RA, Hartung HP, Meergans M, Ortler S, Tracik F. [Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval]. Nervenarzt. 2012;83(12):1575-81 ...
Ten (10) patients with uncontrolled persistent moderate to severe CD were treated with QBECO through a compassionate use program. Patients may have continued to receive conventional medical treatments and/or complementary therapies in addition to the SSI treatment. Seven of the ten patients reported full resolution of clinical symptoms with a course of QBECO treatment of three months or more. Four of these patients have had sustained clinical remission after discontinuing all medications including SSI treatment. The longest case of clinical remission reported is still ongoing, after almost 3 years. Three of the seven patients reporting full remission had follow-up colonoscopies or CT scan with confirmation of full remission. Nine of the ten patients were able to discontinue all other medications at some point while on QBECO treatment. (More information here: http://www.qucrohnstrial.com/ssi-int...cy-and-safety/ ...
Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S. - Ionis plans to open multiple sites in the U.S.
LAVAL, QC, May 3, 2016- Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA.
Executive Director; Medical Strategy- Boston Duties and Responsibilities: Serve as U.S. Medical Director for multiple global clinical development trials and/or U.S. Medical Affairs Trials (including phase I-IV, Expanded Access, Investigator Initiated, registries and Compassionate Use). Interface with Global and U.S. … Read More. ...
The Department of Surgery Clinical Research Program provides faculty and staff with comprehensive support to conduct clinical research studies at the University of Wisconsin.. The Department of Surgery Clinical Research Program is committed to conducting the highest quality clinical research and offering innovative new therapies to our patients, aiming to improve short and long-term patient outcomes. The dedicated clinical research staff has extensive experience in all areas of pharmaceutical and device research including Phase 1 through Phase 4 drug development, compassionate use protocols, investigator held IND studies, bioequivalence and pharmacokinetic studies, and IDE device studies.. ...
Liverpool and London, UK - November 3 2015: The INSPIRE consortium, led by Videregen Ltd, has received approval from the MHRA* to start a UK clinical trial with its tissue engineered replacement trachea. The trial, which is expected to start in the first half of 2016, will focus on severe structural airway disease (SSAD), a potentially life-threatening condition believed to affect 19,000 people in Europe and the US. Along with Videregen as commercial partner, the consortium includes the Cell Therapy Catapult, University College London (UCL), NHS Blood and Transplant in Speke and the Royal Free London NHS Foundation Trust.. The Phase I trial, which will recruit four patients with SSAD, is to assess the safety and initial efficacy of the product. While replacement trachea technologies have been tested previously in compassionate use cases, this is the first formal clinical trial of a tissue engineered autologous stem cell trachea replacement. The INSPIRE project started in 2014, and has £1.9m of ...
Thats a very valid surprise point actually. The FDA emergency approved basically for or based upon four reasons/principals in consideration, parts of the same basic principals they consider in the thought process for all emergency approvals under FDA compassionate use rules to save a life. The first principal being safety, a bio-absorbable plastic was used which has already been in use within the medical area and known to be safe, and the procedure can be accomplished safely. The second principal being commonality to existing medical process/procedure, the application/methodology/theory use of such devices/methods (not necessarily this particular device) is not that uncommon, for example, stints used for heart arteries (in the opening artery up aspect and known to be safely beneficial to health and life), and tracheal implants have already been approved (the first one done in the U.S. basically used the patients own stem cells to produce tissue over a plastic scaffold and others have been ...
America has a major cancer problem America, Please help cure this young lady Mikaela, whos developed kidney cancer! Give My Wife a Chance against Cancer: Please Grant Compassionate Use of MK-3475 for Mikaela Right Away https://www.change.org/petitions/merck-please-grant-compassionate-use-of-mk-3475-for-mikaela-right-away#shareUnfortunately, due to my own life altering experience from a medical device, I do not agree with non-clinically, or clinically tested drugs that…
I agree to provide the physician with any and all copies of my MEDICAL RECORDS, if they exist, that document my medical conditions, as requested by the physician. I agree to obtain medical FOLLOW-UP at my personal medical doctors office or obtain a personal doctor if I have none now and to return for FOLLOW-UP, as recommended by the physician. I understand this is an obligation to MY part for the continuity of care. I understand that I must be a California State resident to obtain an approval or recommendation for the use of cannabis (i.e., Medical Marijuana) under Californias Compassionate Use Act of 1996 (Health & Safety Code #11362.5). I have found or am interested in determining whether cannabis (i.e., medical marijuana) provides substantial relief and improvement of my condition. I have been assured that medical records relating to my care will be kept private and confidential and that no information will be printed, which would disclose my personal identity unless required by law. ...
I agree to provide the physician with any and all copies of my MEDICAL RECORDS, if they exist, that document my medical conditions, as requested by the physician. I agree to obtain medical FOLLOW-UP at my personal medical doctors office or obtain a personal doctor if I have none now and to return for FOLLOW-UP, as recommended by the physician. I understand this is an obligation to MY part for the continuity of care. I understand that I must be a California State resident to obtain an approval or recommendation for the use of cannabis (i.e., Medical Marijuana) under Californias Compassionate Use Act of 1996 (Health & Safety Code #11362.5). I have found or am interested in determining whether cannabis (i.e., medical marijuana) provides substantial relief and improvement of my condition. I have been assured that medical records relating to my care will be kept private and confidential and that no information will be printed, which would disclose my personal identity unless required by law. ...
There has been a lot of recent controversy surrounding the experimental treatment in clinical trials known as GM604. A lot of misinformation has been tossed around on both sides of the issue. I want to beg your attention for a little while to explain whats really going on. First, as many of you know, I was the single late-stage PALS who received GM6 in compassionate use. The intent behind this was to get a look at differences in biomarker candidate levels between earlier-stage and late-stage PALS. Any outward physical manifestation of improved condition noticed would be a bonus and, due to my advanced condition, no improvement in condition was expected. Nevertheless, Genervon and I came up with the idea to try to chart improvements in the tongue. The rationale is that since my tongue is only moderately affected, and because the hypoglossal nerve contains one of the shortest motor neurons in the body, any possible improvement would be noticed there first.. Because of my growing cooperative ...
Remdesivir (GS-5734) is an adenosine analog antiviral drug that inhibits viral RNA polymerase and has demonstrated in vitro activity against various viruses including Ebola, SARS-CoV, and Middle Eastern respiratory syndrome (MERS-CoV). More recently, remdesivir has demonstrated potent activity against SARS-CoV-2 in in vitro and animal model studies, and holds some promise for treatment of COVID-19.2,3 A recent case series describing the compassionate use of remdesivir in 61 adult hospitalized patients with COVID-19 demonstrated that 68% of patients experienced an improvement in the need for oxygen support over a median 18 day follow-up period, while 15% of patients clinically worsened. Clinical improvement was observed in 84% of patients, but was less frequent among older patients (70 or older vs less than 50), and in patients who were on invasive ventilation compared with patients on noninvasive ventilator support. Mortality occurred in 13% of patients, with older patients (70 or older) and ...
The condition Charlie suffers from, "infantile onset encephalomyopathy DNA mitochondrial depletion syndrome," is incurable and ultimately fatal. An experimental therapy is available in the US, but has not as yet been demonstrated in randomised, controlled trials to be safe and effective, and thus remains outside the canon of approved treatments; Columbia University professors had agreed to allow compassionate use for little Charlie, and a "Go Fund Me" charity was set up that would have more than paid for the expense of bringing the child and his parents to New York, but in the UK, doctors can block treatments, even if the parents wish that their child receive them, if they decide that the treatments are not in "the best interests" of the child. ...
The condition Charlie suffers from, "infantile onset encephalomyopathy DNA mitochondrial depletion syndrome," is incurable and ultimately fatal. An experimental therapy is available in the US, but has not as yet been demonstrated in randomised, controlled trials to be safe and effective, and thus remains outside the canon of approved treatments; Columbia University professors had agreed to allow compassionate use for little Charlie, and a "Go Fund Me" charity was set up that would have more than paid for the expense of bringing the child and his parents to New York, but in the UK, doctors can block treatments, even if the parents wish that their child receive them, if they decide that the treatments are not in "the best interests" of the child. ...
Existing law, the Compassionate Use Act of 1996, an initiative measure enacted by the approval of Proposition 215 at the November 6, 1996, statewide general election, authorizes the use of cannabis for medical purposes and provides certain protections to a physician and surgeon who recommends the use of medical cannabis to a patient. The Control, Regulate and Tax Adult Use of Marijuana Act of 2016 (AUMA), an initiative measure approved as Proposition 64 at the November 8, 2016, statewide general election, authorizes a person who obtains a state license under AUMA to engage in commercial adult-use cannabis activity pursuant to that license and applicable local ordinances. The Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA), among other things, provides for the licensure and regulation of commercial medicinal and adult-use cannabis activities and states that the purpose and intent of MAUCRSA is to establish a comprehensive system to control and regulate the cultivation, ...
http://www.hhs.gov/about/ So exactly when does your agency/bureaucracy actually do something helpful and effective "for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves"? It has been two (2) years now that Ive been on this project advocating and writing to former Secretary Kathleen Sebelius and you. My original pleas were for "Compassionate Use" only to learn all along your CMS agency incorporates the doctrine of "Continuity of care" which rightfully should have insured medical coverage for this unique population of patients implanted with a medical device being denied care and/or replacement by your various contractors. The decision of December 30, 2014 reiterates this fact of "Continuity of care". What does it take to get any of you people to understand that it is rightfully your responsibility to care for these patients (read youre agencies statement at the beginning of this communication) and you folks ...
1Note.-. A. Section 1, ch. 2017-232, provides that "[i]t is the intent of the Legislature to implement s. 29, Article X of the State Constitution by creating a unified regulatory structure. If s. 29, Article X of the State Constitution is amended or a constitutional amendment related to cannabis or marijuana is adopted, this act shall expire 6 months after the effective date of such amendment." If such amendment or adoption takes place, s. 381.986, as amended by s. 1, ch. 2017-232, will read:. 381.986 Compassionate use of low-THC and medical cannabis.-. (1) DEFINITIONS.-As used in this section, the term:. (a) "Cannabis delivery device" means an object used, intended for use, or designed for use in preparing, storing, ingesting, inhaling, or otherwise introducing low-THC cannabis or medical cannabis into the human body.. (b) "Dispensing organization" means an organization approved by the department to cultivate, process, transport, and dispense low-THC cannabis or medical cannabis pursuant to ...
Texas Title 6. Food, Drugs, Alcohol, And Hazardous Substances Title 3. Health Professions - Subtitle J. Pharmacy and Pharmacists - Chapter 551. General Provisions Title 3. Health Professions - Subtitle B. Physicians - Chapter 169. Authority to Prescribe Low-thc Cannabis to Certain Patients for Compassionate Use
... Medical Marijuana Outlets On Hold Posted by CN Staff on April 14, 2005 at 09:36:07 PT By Steve Irsay, Staff Writer Source: Grunion Gazette California -- When California voters approved Proposition 215, better known as the Compassionate Use Act of 1996, they decriminalized the personal possession of marijuana for documented medical uses. What they did not do was lay out specific guidelines for getting the drug into the hands of patients. Last year s follow-up statute, SB 420, outlined identification card systems and minimum legal amounts to possess but, again, distribution instructions remained vague. The matter is further complicated by federal law, which prohibits the possession, cultivation and distribution of marijuana. The U.S. Supreme Court is expected to rule shortly on the case of two California medical marijuana users challenging the ban.In this absence of clear retail sales options, many patients have resorted to illegal street ...
In Poland, at The Hirszfeld Institute and of Immunology and Experimental Therapy, phage therapy is carried out under medical experimentation, ethical and compassionate use regulatory provisions similar to those that exist in most countries. A broad range of infections have been treated since the initial anti-staphylococcal treatment in 1925. The Institute requires that all patients treated must have previously been treated - unsuccessfully - with conventional methods such as antibiotics. Since the 1980s, their work with phages has been published in English language scientific journals. Very high success rates - 85% on average - have been obtained for infections caused by bacteria such as Escherichia, Klebsiella, Proteus, Enterobacter, Pseudomonas, and Staphylococcus aureus. Their success rates for treating Pseudomonas aeruginosa and Staphylococcus aureus, including MRSA strains, have been reported to be even higher than 85%.. ...
Does anybody know what the recommmended drug for gastro is currently , (in the US)?? , I know when I had it years ago I took propulsid but it is now on , special case only usage. , One (or more) of my kids has a mitochondrial metabolic disorder which , causes weakness and all kinds of strange side effects, in this case , the equivelence of gastro. , The doctor recommended reglan but this seems to put the poor kid to , sleep (and as soon as she wakes up she has to take the next one). There is no replacement drug. Propulsid is available from Janssen for compassionate use. Erythromycin has the same action. Reglan is not as effective and is a depessant drug. Perhaps you can get Propulcid in Mexico or Europe. I think it has been removed from the Canadian Health System Formulary. spot A. L. Bender, M. D. email @ redacted ---------------------------------------------------------- for HELP or to subscribe/unsubscribe, contact: [email protected] send a DONATION ...
Community-based organization that promotes guidelines for medical marijuana patients to be presumed in compliance with California HS 11362.5, known as the voter-approved Prop 215, the Compassionate Use Act of 1996. ...
Applications for annual licenses will be accepted through an online licensing system that will launch in December 2017. This application will require information on the business, owners and financial interest holders, and operating premises, as well as descriptions of procedures for waste disposal, inventory and quality control, transportation and security. Businesses in operation under the Compassionate Use Act prior to September 1, 2016, will receive priority application review. Applicants must be in compliance with city or county ordinances. During the application review process, CDPH will contact the city or county to verify the local authorization. If the applicant does not provide a copy of their local authorization, the local office will have 60 days to respond. If the applicant includes a copy of their local authorization with their application, the local office will have 10 days to respond. ...
New Jersey added a new herb to its state garden last Tuesday when Gov. Jon S. Corzine signed the New Jersey Compassionate Use Medical Marijuana Act on his last day in office. But though 14 states...
The Times of Trenton Op-Ed. Wednesday, November 24, 2010. SPECIAL TO THE TIMES. The proposal by the state Board of Medical Examiners (BME) to make New Jersey doctors try to wean their patients off of medical marijuana every three months is simply another example of how the crafting of medical marijuana regulations is being driven by fear, ignorance and hostility ("Christie: Tighten rules on medical marijuana," Nov. 16).. The New Jersey Compassionate Use Medical Marijuana Act is already the most restrictive of all such laws in the nation. The qualifying conditions are severely limited and include any patient with a diagnosis of less than 12 months to live. Now the BME is insisting that doctors periodically stop a medication that brings relief to a dying patient "in an effort to reduce the potential for abuse or dependence." It is absurd and cruel. Drug dependence is simply not an issue for a patient with only months to live.. Another qualifying condition is seizures, including epilepsy. After all ...
If you suffer from a debilitating illness take a look at some of the videos and links and feel free to contribute to this discussion by posting in the comments section below. http://www.cannabisinternational.org/ The U.S. Compassionate Use Act and Multiple Sclerosis are two main factors that we think of when we hear so-called experts discussing…